Atherosclerosis is a degenerative process affecting large-and medium-caliber arteries, such as aorta, coronary, carotid, renal, and femoral arteries. The atherosclerotic lesion, or plaque, is a complex tissue dissecting the subendothelial layer and expanding first outwardly and eventually toward the lumen, causing occlusions ranging from minimal to complete. Ischemic consequences of plaque growth represent the major cause of disease, hospitalization, lost productivity, and death in both the industrialized and developing world. In the US (2006 data), ischemic cardiovascular disease (CVD) and stroke combined are a more common cause of death than accidents in people aged 45-54 years, and the major cause of death for all age groups older than 55 years of age. 
There are two types of plasma lipoproteins, those that contain apolipoprotein B (apoB), which include chylomicrons, very-low-density lipoprotein (VLDL), intermediate-density lipoproteins (IDL), and low-density lipoprotein (LDL), and those that contain apolipoprotein AI (apoAI), namely high-density lipoprotein (HDL). The apoB lipoproteins are in general considered as causative of atherosclerosis via the delivery of lipid cargo to the vessel wall, whereas a protective value is attributed to apoAI lipoproteins because they can extract cholesterol out of the plaque. This is the main reason why preventive approaches focus on lowering LDL cholesterol (LDL-C) and increasing HDL cholesterol (HDL-C).
ApoB lipoproteins are produced by the liver (VLDL, IDL, LDL) or by the intestine (chylomicrons and their remnants, not present in the fasting serum). VLDL carries the bulk of fasting triglycerides (TG), whereas LDL is a cholesterol-rich particle derived from the complete TG hydrolysis of VLDL. ApoAI lipoproteins (HDL) are considered to be a protective agent against vascular degeneration because they can acquire cholesterol from peripheral tissues, including the atheroma (arterial plaque), and can carry it back into the liver. 7 Epidemiology has provided strong evidence in support of a direct association between CVD rates and LDL-C levels. This association appears to be due to causation, as it is also found in Mendelian randomization studies where the LDL trait is set at birth by the presence of gene mutations. 8 Studies of LDL-C lowering have incontrovertibly confirmed the causative role of LDL in atherogenesis and its value as a target of therapy. 9 Epidemiology has also strongly linked HDL-C levels and CVD rates in an inverse correlation. However, genetic epidemiology studies have not clearly confirmed the causative nature of the association, 10, 11 and clinical trials have yet to provide evidence that raising HDL-C levels reduces CVD rates. 12 The current risk management guidelines support a multifaceted strategy of early initiation of lifestyle measures, appropriate control of diseases such as hypertension and diabetes, and targeting lipid goals. All guidelines endorse a primary goal of LDL-C reduction to a risk appropriate level, as low as 70 mg/dl in the highest-risk individuals (CVD patients with diabetes or multiple risk factors), and a secondary goal of TG and HDL management (as separate targets or as non-HDL cholesterol). 13 Goal attainment strategies are additional to classic disease management paradigms that traditionally address severe genetic dyslipidemias such as familial hypercholesterolemia, familial combined dyslipidemia, familial hypertriglyceridemia, chylomicronemia, and low HDL syndromes.
Current Therapeutic Approaches
It is well established that interventions based on dietary changes, increased physical activity, smoking cessation, and weight loss cause only moderate LDL-C lowering-usually no more than 10 %-although more aggressive regimens such as the portfolio diet have shown stronger effects in the short term. 14 
Intestinally Acting Agents
These include the bile acid binding resins, colestipol, cholestyramine, and colesevelam, and the intestinal absorption inhibitor, ezetimibe.
These agents reduce LDL cholesterol by 15-20 % at full dose, and have minimal-to-no effects on TG and HDL-C levels. Since there is no redundancy of mechanism of action between the resins and ezetimibe, the two agents could be combined to maximize the non-systemic approach to cholesterol control in statin-resistant patients. Studies have been published on the effectiveness of combining resin therapy and ezetimibe on LDL-C levels, 16 but the resin may interfere with absorption of ezetimibe. Resins have provided evidence of CVD benefits in the general population, 17 whereas ezetimibe has recently been proven to reduce CVD risk in renal patients when used in combination with simvastatin. Niacin use has been shown to reduce CVD rates and total mortality. 20, 21 In combination with simvastatin, it has proven superior to ezetimibe in reducing carotid intima-media thickness over a period of two years. 22 A large National Institutes of Health (NIH)-funded trial investigating the role of extended-release niacin in combination with simvastatin on CVD rates in a cohort of high-risk patients 23 has recently been halted due to lack of clinical efficacy. 24 
Fibrates
There are three fibrate agents on the US market: generic gemfibrozil, generic fenofibrate, and a patent-protected formulation of fenofibric acid. The fibrates activate the nuclear transcription factor peroxisome proliferator-activated receptor (PPAR)α, which causes the upregulation of several genes including some that control lipoprotein metabolism.
The effect of fibrates on LDL-C is highly variable because the majority of patients with high triglycerides have artificially low LDL-C and adjustment of TG produces compensatory elevations in LDL-C. By and large, only modest LDL-C reductions (10 %) are expected by fibrate therapy even in the absence of severe hypertriglyceridemia, and thus these agents are not commonly used for LDL-C management. Type A evidence of CVD risk reduction has been produced with gemfibrozil [25] [26] [27] but not with fenofibrate. 28, 29 Fenofibric acid has not been studied in clinical trials of CVD risk reduction.
Omega 3 Fatty Acids
Although a staple of CVD risk reduction maneuvers, use of high-dose fish oils for lipid management is reserved for high TG levels. No LDL-C reduction is reported with formulations enriched in both eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), 30, 31 whereas DHA-only containing agents claim a small but significant LDL-C reduction effect. 32 Omega 3 fatty acids have provided evidence of benefits on CVD rates, but not through lipid-lowering effects.
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Statin Therapy
Statins inhibit cholesterol synthesis via blockade of the enzyme 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase.
Consequently, the inability of the liver to make its own cholesterol 
Efficacy
It is beyond the scope of this short paper to review all the landmark trials that have led to the current acceptance of statins as mandatory agents for CVD risk reduction in most patients. Briefly, the story started in 1994 with the publication of the Scandinavian simvastatin survival study (4S) trial, which showed large mortality benefits from simvastatin 20/40 mg, versus placebo, in survivors of myocardial infarction (MI) with a baseline LDL-C around 190 mg/dl. 36 This was followed by the West-of-Scotland coronary prevention study (WOSCOPS) showing that pravastatin 40 mg, versus placebo, reduced risk of the first MI in healthy subjects with severe hypercholesterolemia (LDL-C around 190 mg/dl). 37 The Cholesterol and recurrent event (CARE) study 38 showed the benefits of pravastatin 40 mg, versus placebo, in reducing recurrent events in coronary artery disease (CAD) patients with mild hypercholesterolemia (LDL-C around 140 mg/dl), while the Air Force/Texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS) 39 showed the value of lovastatin 40 mg in reducing the risk of first CVD event among healthy subjects with mild hypercholesterolemia (LDL-C around 150 mg/dl). The new millennium brought the Heart protection study (HPS), 40 showing that simvastatin 40 mg greatly reduces CVD event rate in high-risk patients, including patients with diabetes, even though baseline LDL-C was only about 120 mg/dl. This study introduced the concept of a lower therapeutic threshold for LDL-C control, as safety and benefits were obvious also for subjects reaching LDL-C below 70 mg/dl. This concept was confirmed and amplified by the Treatment to new targets (TNT) trial, which showed that atorvastatin 80 mg is superior to atorvastatin 10 mg in reducing CVD event rates among high-risk patients with stable coronary disease by virtue of on-treatment LDL-C levels close to the threshold of 70 mg/dl (compared with 100 mg/dl). 41 This same idea was also validated for patients with unstable plaques causing acute where there was no difference in the prevalence of muscle complaints between subjects taking 40 mg simvastatin and those taking placebo over a period of five years, and only 0.5 % of treatment-assigned subjects discontinued the drug because of muscle problems. 48 Real-world estimates of severe muscle complaints leading to discontinuation of the statin and undertreatment of at-risk subjects place that figure well above 10 %. 49 The other main toxicity problem with statin use is linked to liver function test 
A New Statin-Pitavastatin
Pitavastatin was approved in Japan in 2003 and has since been approved in South Korea, Thailand, China, Europe, and the US. The FDA has approved pitavastatin at the doses of 1 mg, 2 mg, and 4 mg for patients with primary hyperlipidemia and mixed dyslipidemia as an adjunctive to diet to reduce elevated total cholesterol, LDL-C, apoB, and TG, and to increase HDL-C. Pitavastatin has a novel structure (a synthetic cyclopropyl side group) that gives it unique properties to set it apart from other statins, including enhanced potency, minimal cytochrome P450 (CYP) metabolism, increased bioavailability, and reduced risk of CYP-mediated pharmacokinetic interactions. Pitavastatin is a more potent inhibitor of HMG-CoA reductase than simvastatin (>two-fold) and pravastatin (>six-fold), and causes increased LDL receptor mRNA expression, increased degradation of apoB, and reduced secretion of VLDL in human hepatoma HepG2 cells. 50 The effect of pitavastatin on HDL-C may be driven by induced expression of apoAI. 51 Pitavastatin is highly bioavailable (51 %), mostly protein bound (>99 %), and uniquely metabolized. 52 Whereas most statins use the CYP system as the predominant metabolic route, pitavastatin is mostly metabolized by glucuronidation via uridine 5'-diphosphate glucuronosyltransferase (UGT), isoforms 1A3 and 2B7. 52 Pitavastatin does not utilize the CYP3A4 pathway (which metabolizes lovastatin, simvastatin and atorvastatin) and only marginally utilizes CYP2C9 (which metabolizes fluvastatin and rosuvastatin) and, to a lesser extent, CYP2C8. 52, 53 Pitavastatin is mostly excreted unchanged in the bile and undergoes entero-hepatic recirculation after intestinal re-absorption. 54 Only a small fraction (<3 %) of pitavastatin is excreted in the urine. In Table 1 ). 50, 52 Pitavastatin is transported by the organic anion-transporting polypeptides (OATP) 1B1, 1B3, and 2B1, and the sodium taurocholate co-transporting polypeptide (NTCP) from the plasma to the liver, and by breast cancer resistance protein (BCRP) and multidrug resistance-associated protein 2 (MRP2) and multidrug resistance protein 1 (MDR1) from the liver to the bile. 56-58 The 4.6-fold increase in AUC for pitavastatin compares to six-and seven-fold increases for atorvastatin and rosuvastatin, respectively. 59, 60 Although pitavastatin undergoes minimal metabolism through the CYP system, it must be kept in mind that drug-drug interactions may involve the interaction of influx and/or efflux transporters. Pitavastatin is contraindicated in patients taking cyclosporine. Also, the FDA recommends a maximum dose of 1 mg and 2 mg, respectively, for patients taking erythromycin or rifampin.
Comparative Efficacy of Available Statins
A series of phase III 12-week studies were performed to compare the lipid-lowering efficacy of pitavastatin with that of equipotent doses of atorvastatin, simvastatin, and pravastatin based on LDL-C reduction.
These studies aimed at testing the non-inferiority of pitavastatin versus the comparator on mean per cent change in LDL-C, defined as a differential of less than 6 % in LDL-C reduction in favor of the comparator. 61 Study drug comparisons were pitavastatin 1 mg versus pravastatin 10 mg; pitavastatin 2 mg versus atorvastatin 10 mg, non-inferiority between pitavastatin and atorvastatin or simvastatin, and superiority for pitavastatin versus pravastatin (see Figure 1) . The 1 mg dose of pitavastatin has lipid effects similar to those of pravastatin 40 mg. In these studies, the most common adverse reactions were constipation, back pain, diarrhea, pain in extremities and myalgia.
Discontinuation rates were low with the most common reasons being elevated CPK (0.6 %) and myalgia (0.5 %) at the highest pitavastatin dose.
In other studies performed outside the US, such as the Collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA) trial, subjects taking pitavastatin 2 mg or atorvastatin 10 mg were followed for 12 weeks for efficacy and safety parameters. There were no significant differences between the two regimens in non-HDL-C, total cholesterol, LDL-C, and TG changes, whereas HDL-C was significantly increased, though modestly, only by pitavastatin (p=0.033). There were no safety concerns with either drug, but LFT levels on average increased with atorvastatin and did not with pitavastatin. 62 Another study, a parallel group comparison of the tolerability and effects of pitavastatin and atorvastatin on HDL-C levels and glucose metabolism in Japanese patients with elevated levels of LDL-C and glucose intolerance (PIAT), compared pitavastatin 2 mg and atorvastatin 10 mg in 207 patients with pre-diabetes over a period of 52
weeks. Both statins produced significant lipid changes compared with baseline, but atorvastatin was superior to pitavastatin on LDL-C, non-HDL-C, and apoB reduction, whereas pitavastatin was superior to atorvastatin on HDL-C increases and increases in apoAI levels. 63 A recent post hoc analysis of the change in fasting glucose levels in patients with type 2 diabetes mellitus showed a significant increase with atorvastatin over 12 weeks versus no change with pitavastatin. 64 A surveillance study, LIVALO effectiveness and safety (LIVES), has followed nearly 20,000 patients on pitavastatin for two years. Most subjects were on the 1 mg or 2 mg dose. Lipid changes were in line with those obtained in the different phase III trials, and safety records showed a 0.14 % prevalence of serious adverse events and a 7.4 % discontinuation rate based on any adverse event. Increases in CPK, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were reported in 2.7 %, 1.8 %, and 1.5 % of subjects, respectively.
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Pitavastatin and Clinical Endpoints
Pitavastatin has yet to show reduction in CV risk either in stable CAD patients, subjects with acute coronary syndrome (ACS), or in primary prevention settings. The Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) study has, shown that pitavastatin upregulates expression of hormone-sensitive lipase, prevents TG accumulation, and reduces the expression of the adipocyte fatty acid binding protein 2 (aP2) in obese mice. 70 Since aP2
is a major transductor of the effects of insulin resistance on the vessel wall, [71] [72] [73] it is possible that pitavastatin may improve insulin sensitivity and exert an enhanced vascular protection in patients with diabetes.
It is worth noting that two recent large meta-analyses of statin trials actually suggest a diabetogenic effect of statins. 74, 75 Against this background, pitavastatin may show divergence of effects with other statins, an important clinical niche of use. In the LIVES surveillance program, average glycosylated hemoglobin (HbA 1c ) decreased over two years in the 6,000 or so patients on pitavastatin. 65 This issue will be studied prospectively in the Japan prevention trial of diabetes by pitavastatin in patients with impaired glucose tolerance (J-PREDICT), where pitavastatin will be compared with lifestyle measures for preventive effects against the incidence of diabetes in a population with impaired glucose tolerance at baseline.
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Summary and Conclusions
Pitavastatin 
